TNBC

New York, USA, July 10, 2023 (GLOBE NEWSWIRE) -- Triple-Negative Breast Cancer Clinical Trial Pipeline Insights Featuring 75+ Companies | DelveInsight The prevalence of triple-negative…

Physician’s Briefing Staff FRIDAY, Aug. 19, 2022 (HealthDay News) -- Among patients with early-stage triple-negative breast cancer (TNBC), the…

Pembrolizumab (Keytruda) added to first-line chemotherapy significantly improved overall survival (OS) for…

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been…

Pembrolizumab (Keytruda) plus chemotherapy as first-line treatment significantly improved overall survival (OS) for patients with…

Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for…

Neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, continued as a single agent after…